10-Q: Hims & Hers Health Reports Strong Q1 2025 Results, Revenue Jumps 111%

Hims & Hers Health, Inc. announces a significant increase in revenue and subscribers for the first quarter of 2025, driven by growth in online revenue and the introduction of new weight loss solutions.

Summary

• Hims & Hers Health, Inc. reported a 111% increase in revenue for the first quarter of 2025, reaching $586.0 million compared to $278.2 million in the same period last year.
• Online revenue increased by 115% to $576.4 million, driven by new subscriber growth and the success of weight loss solutions, particularly compounded semaglutide GLP-1 offerings.
• Subscribers grew by 38% to 2.4 million as of March 31, 2025.
• Monthly Online Revenue per Average Subscriber increased to $84, a 53% increase compared to $55 in the first quarter of 2024.
• Net income for the quarter was $49.5 million, a significant increase from $11.1 million in the prior year.
• Adjusted EBITDA reached $91.1 million, compared to $32.3 million in the first quarter of 2024.
• The company acquired certain manufacturing assets from C S Bio Co. and all membership interests of Trybe Labs in February 2025.
• A new revolving credit facility of $175.0 million was established in February 2025.
• Nader Kabbani was appointed as chief operating officer, effective May 19, 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and strategic acquisitions. However, there are some risks and challenges, such as the FDA's decision regarding semaglutide and the competitive landscape, which temper the overall sentiment.

Positives

• Significant revenue growth driven by online sales and new weight loss solutions.
• Substantial increase in subscribers, indicating strong customer acquisition and retention.
• Improved profitability with a significant increase in net income and Adjusted EBITDA.
• Strategic acquisitions to strengthen supply chain capabilities and expand service offerings.
• Establishment of a new credit facility to support future growth and operations.
• Appointment of a new chief operating officer with extensive experience in operations and logistics.

Negatives

• Gross margin decreased from 82% to 73%, primarily due to the addition of newer offerings priced to attract new customers.
• Wholesale revenue decreased by 7% compared to the same period last year.
• The FDA resolved the semaglutide shortage, which has constrained and is expected to continue to constrain the company's ability to provide access to compounded semaglutide on its platform.

Risks

• The company's ability to provide access to compounded semaglutide on its platform is constrained due to the FDA resolving the semaglutide shortage.
• The company operates in a highly competitive market and faces competition from large, well-established healthcare providers, traditional retailers, pharmaceutical providers and technology companies with significant resources.
• The company is subject to numerous federal, state, and local laws and regulations that carry substantial criminal and civil fines and penalties.
• Security breaches, loss of data, and other disruptions could compromise sensitive information related to the company's business or customers.
• The market price of the company's Class A common stock may be volatile.

Future Outlook

The company expects to continue investing in growth, including expanding its fulfillment capabilities, marketing efforts, and product offerings. The company also expects to retain a significant majority of revenue from Subscribers who maintain a Subscription for more than two years. The company expects Monthly Online Revenue per Average Subscriber to decrease in the near term relative to the first quarter of 2025 and normalize over the long term due to the FDA resolving the semaglutide shortage.

Management Comments

• Management monitors Online Revenue and Wholesale Revenue to track total revenue generation.
• Management primarily uses the Subscribers and Monthly Online Revenue per Average Subscriber metrics to manage and monitor the performance of the business.

Industry Context

The telehealth and pharmaceutical industries are highly competitive and subject to rapid change. Hims & Hers faces competition from traditional healthcare providers, pharmacies, and technology companies. The company's success depends on its ability to differentiate itself through accessibility, affordability, personalization, and brand recognition.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• A comparison would require data on revenue growth, subscriber acquisition costs, and profitability metrics of comparable telehealth and pharmaceutical companies.
• Companies like Teladoc Health, Amwell, and GoodRx could be considered comparables, but a thorough analysis would need to consider differences in business models and target markets.
• The company's focus on personalized solutions and direct-to-consumer approach differentiates it from some traditional healthcare providers.

Management Changes

Legal Proceedings

• The company is subject to legal proceedings in the ordinary course of business, but management is not aware of any matters that are reasonably likely to have a material adverse impact on the company's business, financial position, results of operations, or cash flows.

Related Party Transactions

• The company recorded $1.4 million within operating expenses for payments made to Woolly Labs, Inc. (d/b/a Vouched), a related-party company that provides identity verification services.

Stakeholder Impact

• Shareholders: Positive results may lead to increased stock value.
• Employees: Continued growth may lead to more job opportunities and career advancement.
• Customers: Expansion of services and improved platform may enhance customer experience.
• Suppliers: Increased demand may lead to more business opportunities.
• Creditors: Strong financial performance may improve creditworthiness.

Next Steps

• Continue to invest in fulfillment, distribution, and operating capabilities.
• Expand into new health and wellness specialties.
• Continue to evaluate the likelihood of achieving performance metrics related to performance RSUs on a quarterly basis.
• Continue to evaluate the likelihood of achieving the performance metrics on a quarterly basis.

Key Dates

Keywords

revenue, subscribers, Hims & Hers, GLP-1, weight loss, telehealth, Adjusted EBITDA, acquisitions, pharmacy, credit facility